Bioengineering Prourokinase for Improved Fibrinolysis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL075883-01
Award Id:
70917
Agency Tracking Number:
HL075883
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
PROTEOMTECH, INC., 5980 HORTON ST, STE 405, EMERYVILLE, CA, 94608
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
DANIEL MEDYNSKI
(510) 597-9139
MEDYNSKI@PROTEOMTECH-INC.COM
Business Contact:
AMY PFEIFFER
(510) 597-9133
PFEIFFER@PROTEOMTECH-INC.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The objective of this proposal is to bioengineer a mutant variant of prourokinase (proUK) with improved therapeutic properties for treatment of acute myocardial infarction(AMI). ProUK is unique among thrombolytic agents in that it is stable as an inert zymogen in blood plasma before activation and conversion to urokinase (UK) at the site of a fibrin blot clot, at least under physiological concentrations. There are several discrete properties of proUK which we have targeted for improvement: (a) increased fibrin specificity, (b) increased resistance to natural inhibitors such as plasminogen activator inhibitor (PAI), (c) reduced nonspecific systemic bleeding, (d) increased half life, and (e) single bolus administration. Bioengineered versions of tissue plasminogen activator (tPA) which have been introduced into the clinic recently, such as Tenecteplase and Reteplase, do not adequately fulfill these ideal properties, so there is ample opportunity to develop other therapeutics with superior qualities, such as bioengineered proUK. The bioengineered variants of proUK will be expressed in E. coli and refolded and purified from insoluble inclusion bodies. We have already refolded and purified wild type proUK from inclusion bodies, and demonstrated that upon activation to UK, the kinetic parameters related to fibrinolysis show excellent agreement with published values. Our company, Proteomtech, is a recognized leader in the area of protein refolding technology from inclusion bodies and has already successfully refolded more than 200 proteins, some at industrial scale. Published studies have established that nonglycosylated wild type proUK and UK expressed in E. coli have superior, quicker, fibrinolytic properties when compared to glycosylated versions expressed in eukaryotic expression systems; the challenge is to increase proUK half life and stability in vivo for the unglycosylated proUK. Our long-term objective is to develop the bioengineered variant for clinical application to AMI with the possibility of extending to other conditions including stroke, peripheral arterial occlusion, and deep vein thrombosis. No preclinical animal studies or human studies are included in this proposal.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government